Molecular biology of otosclerosis

Advances in Oto-Rhino-Laryngology

Volumn 65, Issue , 2007, Pages 68-74

  McKenna, Michael J ^a,b   Kristiansen, Arthur G ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; BONE REMODELING; CARTILAGE; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETICS; HUMAN; MEASLES VIRUS; MIDDLE EAR; OSTEOBLAST; OTOSCLEROSIS; PATHOLOGY; PHYSIOLOGY; TEMPORAL BONE;

BONE REMODELING; CARTILAGE; EAR, MIDDLE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEASLES VIRUS; OSTEOBLASTS; OSTEOPROTEGERIN; OTOSCLEROSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, VIRAL; TEMPORAL BONE;

EID: 33846614170     PISSN: 00653071     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000098674     Document Type: Article

References (48)

1. Quinn JM, Whitty GA, Byrne RJ, Gillespie MT, Hamilton JA: The generation of highly enriched osteoclast-lineage cell populations. Bone 2002;30:164-170.
2. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL: The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-538.
3. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ: Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000;157:435-448.
4. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
5. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T: Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000;141:3478-3484.
6. Zehnder AF, Kristiansen AG, Adams JC, Merchant SN, McKenna MJ: Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. Laryngoscope 2005:115:172-177.
7. Engstrom H: Über das Vorkommen der Otosklerose nebst experimentellen Studien über chirurgische Behandlung der Krankheit. Acta Otolaryngol 1940;43S:1-153.
8. Guild SR: Histologic otosclerosis. Ann Otol Rhinol Laryngol 1944;53:246-267.
9. Pearson RD, Kurland LT, Cody DT: Incidence of diagnosed clinical otosclerosis. Arch Otolaryngol 1974;99:288-291.
10. Albrecht W: Über die Vererbung der hereditären Labyrinthschwerhörigkeit und der Otosklerose. Arch Ohren Nasen Kehlkopfheilkd 1922;110:15-48.
11. Fowler EP: Otosclerosis in identical twins. A study of 40 pairs. Arch Otolaryngol 1966;83:324-328.
12. Hammerschlag V: Zur Frage der Vererbbarkeit der Otosklerose. Wien Klin Radsch 1905;19:5-7.
13. Causse JR, Causse JB: Otospongiosis as a genetic disease. Early detection, medical management, and prevention. Am J Otol 1984;5:211-223.
14. Gapanavichyus BM, Venslauskas MI: Genetic analysis of the inheritance of otosclerosis. Sov Genet 1974;8:251-260.
15. Larsson A: Otosclerosis. A genetic and clinical study. Acta Otolaryngol 1960;154(suppl):1-86.
16. Morrison AW: Genetic factors in otosclerosis. Ann R Coll Surg Engl 1967;41:202-237.
17. Ben Arab S, Besbes G, Hachicha S: Otosclerosis in populations living in northern Tunisia: epidemiology and etiology. Ann Otolaryngol Chir Cervicofac 2001;118:19-25.
18. Chen W, Campbell CA, Green GE, Van Den Bogaert K, Komodikis C, Manolidis LS, Aconomou E, Kyamides Y, Christodoulou K, Faghel C, Giguere CM, Alford RL, Manolidis S, Van Camp G, Smith RJ: Linkage of otosclerosis to a third locus (OTSC3) on human chromosome 6p21.3-22.3. J Med Genet 2002;39:473-477.
19. Tomek MS, Brown MR, Mani SR, Ramesh A, Srisailapathy CR, Coucke P, Zbar RI, Bell AM, McGuirt WT, Fukushima K, Willems PJ, Van Camp G, Smith RJ: Localization of a gene for otosclerosis to chromosome 15q25-q26. Hum Mol Genet 1998;7:285-290.
20. Van Den Bogaert K, Govaerts PJ, Schatteman I, Brown MR, Caethoven G, Offeciers FE, Somers T, Declau F, Coucke P, Van de Heyning P, Smith RJ, Van Camp G: A second gene for otosclerosis, OTSC2, maps to chromosome 7q34-36. Am J Hum Genet 2001;68:495-500.
21. Cawthorne T: Otosclerosis. J Laryngol Otol 1955;69:437-456.
22. Nager FR: Zur klinischen und pathologischen Anatomie der Otosklerose. Acta Otolaryngol 1939;27:542-551.
23. Shambaugh GE: Fenestration operation for otosclerosis. Acta Otolaryngol Suppl 1949;79:1-101.
24. McKenna MJ, Kristiansen AG, Bartley ML, Rogus JJ, Haines JL: Association of COL1A1 and otosclerosis: evidence for a shared genetic etiology with mild osteogenesis imperfecta. Am J Otol 1998;19:604-610.
25. McKenna MJ, Kristiansen AG, Tropitzsch AS: Similar COL1A1 expression in fibroblasts from some patients with clinical otosclerosis and those with type I osteogenesis imperfecta. Ann Otol Rhinol Laryngol 2002;111:184-189.
26. Willing MC, Deschenes SP, Scott DA, Byers PH, Slayton RL, Pitts SH, Arikat H, Roberts EJ: Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen. Am J Hum Genet 1994;55:638-647.
27. Willing MC, Deschenes SP, Slayton RL, Roberts EJ: Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet 1996;59:799-809.
28. Willing MC, Pruchno CJ, Atkinson M, Byers PH: Osteogenesis imperfecta type I is commonly due to a COL1A1 null allele of type I collagen. Am J Hum Genet 1992;51:508-515.
29. Nager GT: Osteogenesis imperfecta of the temporal bone and its relation to otosclerosis. Ann Otol Rhinol Laryngol 1988;97:585-593.
30. Ziyeh S, Berger R, Reisner K: MRI-visible pericochlear lesions in osteogenesis imperfecta type I. Eur Radiol 2000;10:1675-1677.
31. Fowler E: The incidence (and degrees) of blue sclerae in otosclerosis and other ear disorders. Laryngoscope 1949;59:406.
32. Garretsen TJ, Cremers CW: Clinical and genetic aspects in autosomal dominant inherited osteogenesis imperfecta type I. Ann NY Acad Sci 1991;630:240-248.
33. Sykes B, Ogilvie D, Wordsworth P, Wallis G, Mathew C, Beighton P, Nicholls A, Pope FM, Thompson E, Tsipouras P, et al: Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet 1990;46:293-307.
34. McKenna MJ, Nguyen-Huynh AT, Kristiansen AG: Association of otosclerosis with Sp1 binding site polymorphism in COL1A1 gene: evidence for a shared genetic etiology with osteoporosis. Otol Neurotol 2004;25:447-450.
35. Clayton AE, Mikulec AA, Mikulec KH, Merchant SN, McKenna MJ: Association between osteoporosis and otosclerosis in women. J Laryngol Otol 2004;118:617-621.
36. Friedrichs WE, Reddy SV, Bruder JM, Cundy T, Cornish J, Singer FR, Roodman GD: Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res 2002;17:145-151.
37. Mee AP: Paramyxoviruses and Paget's disease: the affirmative view. Bone 1999;24(suppl 5):19S-21S.
38. McKenna MJ, Mills BG: Immunohistochemical evidence of measles virus antigens in active otosclerosis. Otolaryngol Head Neck Surg 1989;101:415-421.
39. McKenna MJ, Mills BG: Ultrastructural and immunohistochemical evidence of measles virus in active otosclerosis. Acta Otolaryngol Suppl 1990;470:130-140.
40. McKenna MJ, Mills BG, Galey FR, Linthicum FH Jr: Filamentous structures morphologically similar to viral nucleocapsids in otosclerotic lesions in two patients. Am J Otol 1986;7:25-28.
41. Karosi T, Konya J, Szabo LZ, Sziklai I: Measles virus prevalence in otosclerotic stapes footplate samples. Otol Neurotol 2004;25:451-456.
42. McKenna MJ, Kristiansen AG, Haines J: Polymerase chain reaction amplification of a measles virus sequence from human temporal bone sections with active otosclerosis. Am J Otol 1996;17:827-830.
43. Niedermeyer H, Arnold W, Neubert WJ, Hofler H: Evidence of measles virus RNA in otosclerotic tissue. ORL J Otorhinolaryngol Relat Spec 1994;56:130-132.
44. Niedermeyer HP, Arnold W: Otosclerosis: a measles virus associated inflammatory disease. Acta Otolaryngol 1995;115:300-303.
45. Lolov SR, Encheva VI, Kyurkchiev SD, Edrev GE, Kehayov IR: Antimeasles immunoglobulin G in sera of patients with otosclerosis is lower than that in healthy people. Otol Neurotol 2001;22:766-770.
46. Vrabec JT, Coker NJ: Stapes surgery in the United States. Otol Neurotol 2004;25:465-469.
47. Frisch T, Sorensen MS, Overgaard S, Bretlau P: Estimation of volume referent bone turnover in the otic capsule after sequential point labeling. Ann Otol Rhinol Laryngol 2000;109:33-39.
48. Frisch T, Sorensen MS, Overgaard S, Bretlau P: Predilection of otosclerotic foci related to the bone turnover in the otic capsule. Acta Otolaryngol Suppl 2000;543:111-113.